低剂量可吸入的氨基酸修饰的多层层纳米颗粒激活STING,可安全有效地回归肺转移
Ruoshi Zhang1, Chengcheng Wu1, Lvshan Yu2
1School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China; Tsinghua-Peking Center for Life Sciences, Beijing 100084, China.
概括
一种新型的氨酸-脂质混合纳米颗粒有效地将STING激动剂 (cGAMP) 输送到肺部,完全消除低剂量和最小副作用的肺转移. 这一突破为肺癌提供了一个有前途的新免疫疗法.
科学领域:
- 纳米医学是一种纳米医学.
- 免疫治疗是一种免疫疗法.
- 肺部药物输送 肺部药物输送
背景情况:
- 肺转移很难治疗,原因是对全身疗法的耐药性和手术的局限性.
- 像循环GMP-AMP (cGAMP) 这样的STING激动剂的肺输送可以激活对转移的局部免疫力.
- 现有的肺输送系统面临着不稳定性,粘液捕获和药物释放不良等挑战.
研究的目的:
- 开发一种可吸入的纳米粒子配方,用于增强cGAMP的肺部输送.
- 为了克服当前传递系统的局限性,提高稳定性,粘液透和细胞质药物释放.
- 评估新型配方在治疗已确定的肺转移中的疗效.
主要方法:
- 开发一种囊括cGAMP的氨酸 (HA) -脂质混合多层纳米粒子 (HLHC).
- 纳米粒子刚性,气溶稳定性和粘液透性的表征.
- 对氨基酸修饰脂质进行查,以获得最佳的细胞质cGAMP输送,识别阿金变异 (Arg-HLHC).
- 在小鼠肺转移模型 (MC38-luc) 中Arg-HLHC疗效的体内评估.
主要成果:
- 这种HA-脂质结构显著增加了纳米颗粒的刚性和肺部保留.
- 与传统的脂质体相比,这种配方在粘液透方面得到了35倍的改善.
- 肺部注射Arg-HLHC (1.5μgcGAMP) 实现了肺转移的100%回归.
- Arg-HLHC的性能优于先进的脂质纳米颗粒,并且在没有系统性炎症的情况下诱导局部STING激活.
结论:
- 开发的Arg-HLHC纳米平台克服了肺性STING激动剂输送的关键挑战.
- 这种模块化系统为肺转移提供了安全,治愈,低剂量治疗策略.
- 这项技术对下一代呼吸道免疫疗法具有广泛的潜力.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
482
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
482
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
464
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
464


